Why Is Eli Lilly and Company (LLY) Stock Down Today?
AI-sourced movement explanations, refreshed three times each trading day · Latest: August 31, 2026
Eli Lilly dips despite Mounjaro's FDA nod, competitive concerns weigh
The Full Story
Eli Lilly (LLY) shares experienced a modest decline of 1.24% today, underperforming a slightly positive sector. While the company recently received positive news regarding Mounjaro's FDA approval for cardiovascular risk reduction, investor sentiment may have been impacted by increasing competitive pressures, particularly from Novo Nordisk.
What's Driving the Move
Competitive Landscape
Concerns over potential catalysts for competitor Novo Nordisk may have contributed to negative sentiment, overshadowing positive company-specific news.
Mounjaro FDA Nod
The positive news of Mounjaro's FDA approval for cardiovascular risk reduction did not prevent the stock's decline, suggesting it may have been priced in or offset by other factors.
Significant Moves — Last 90 Days
Eli Lilly Shares Decline Sharply, Outpacing Sector Downturn
Eli Lilly Surges on Europe's First Weight Loss Pill Approval
Eli Lilly Rises on European Weight Loss Drug Approval
Eli Lilly surges on positive weight-loss drug FDA filing news
Eli Lilly Surges on Strong Q2 Earnings Report
Eli Lilly shares fall sharply amid weight loss drug competition concerns
Previous Sessions
A running log of what moved LLY each trading day.
| Date | Move | What Happened |
|---|---|---|
| Aug 28 | ▼ -0.28% | Eli Lilly sees slight dip, outperforms sector amid growth discussions |
| Aug 27 | ▼ -1.13% | Eli Lilly Outperforms Sector Despite Modest Decline Amidst Growth Prospects |
| Aug 26 | ▼ -3.49% | Eli Lilly Shares Decline Sharply, Outpacing Sector Downturn |
| Aug 25 | ▼ -1.23% | Eli Lilly Dips Modestly, Underperforming Broader Healthcare Sector |
| Aug 24 | ▼ -0.47% | Eli Lilly Experiences Modest Dip Despite Positive Growth Outlook |
| Aug 21 | ▲ +0.75% | Eli Lilly Rises Modestly on European Weight Loss Pill Approval |
| Aug 20 | ▼ -2.64% | Eli Lilly Falls Amid Broader Sector Weakness Despite Positive Drug Approval News |
| Aug 19 | ▲ +4.40% | Eli Lilly Surges on Europe's First Weight Loss Pill Approval |
| Aug 18 | ▲ +3.45% | Eli Lilly Rises on European Weight Loss Drug Approval |
| Aug 17 | ▲ +0.16% | Eli Lilly Edges Up on European Weight Loss Drug Approval |
| Aug 14 | ▼ -2.48% | Eli Lilly Shares Decline on Ex-Dividend Date Amid Broader Market Pressures |
| Aug 13 | ▼ -0.92% | Eli Lilly dips slightly, underperforming positive healthcare sector |
| Aug 12 | ▲ +0.43% | Eli Lilly edges higher amid continued focus on weight-loss drug pipeline |
| Aug 11 | ▼ -1.50% | Eli Lilly Shares Decline Amid Sector Weakness and GLP-1 Competition Concerns |
Frequently Asked Questions
Why is LLY stock down today?
How do you determine why a stock moved?
When is this page updated?
What counts as a significant move?
Methodology
Each trading day we pair LLY’s price and volume action with same-day news coverage, earnings events, analyst actions, and sector context, then generate a sourced explanation using AI with live search grounding. Updates run shortly after the open, midday, and after the close — intraday versions are marked preliminary.
Moves are flagged significant based on their size relative to the stock’s typical daily range. Explanations describe what plausibly drove a move; markets don’t always have a single clean cause.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on LLY
Eli Lilly and Company Overview
Price, chart, analysis & financials
LLY: Overbought or Oversold?
Updated daily
LLY: Price Prediction
Updated daily
LLY: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers